Evaluation of combination of tissue type plasminogen activator, SUN9216, and a thromboxane A_2 receptor antagonist, vapiprost, in a middle cerebral artery thrombosis model in rats

The modified tissue-type plasminogen activator, SUN9216 (SUN), and the combination of SUN and a thromboxane A_2 receptor antagonist, vapiprost (Vapi), were evaluated in rat middle cerebral artery (MCA) occlusion due to photo-chemically induced thrombosis. Under anesthesia, the left MCA was observed...

Full description

Saved in:
Bibliographic Details
Published inJapanese Journal of Pharmacology Vol. 61; no. suppl.2; p. 318
Main Authors Kazuo Umemura, Koichiro Wada, Masayuki Ishiye, Yoshinori Toshima, Toshihiko Uematsu, Mitsuyoshi Nakashima
Format Journal Article
LanguageJapanese
Published The Japanese Pharmacological Society 1993
Online AccessGet full text

Cover

More Information
Summary:The modified tissue-type plasminogen activator, SUN9216 (SUN), and the combination of SUN and a thromboxane A_2 receptor antagonist, vapiprost (Vapi), were evaluated in rat middle cerebral artery (MCA) occlusion due to photo-chemically induced thrombosis. Under anesthesia, the left MCA was observed without cutting the dura mater via a subtemporal craniotomy under an operation microscope (OM). The reopening of MCA by SUN, injected 30 min after the MCA occlusion, was observed under an OM for 60 min. The combination of SUN and Vapi caused reopening of the MCA by 58.8 %, which was greater than that achieved with SUN alone at 31.6%. The infarction area 24 hr after the operation in animals reperfused with SUN was significantly reduced as compared with that in the control. There was a significant correlation between time of reopening and size of infarction.
ISSN:0021-5198